New product update

A round-up of the latest developments in pharmaceuticals, clinical studies and guidance, as reported in MIMS

Molluscum contagiosum: topical treatment showed efficacy (Photograph: Dr P Marazzi/SPL)
Molluscum contagiosum: topical treatment showed efficacy (Photograph: Dr P Marazzi/SPL)

Topical molluscum treatment

MolluDab, a topical solution of potassium hydroxide 5%, has been launched for the treatment of molluscum contagiosum. Applied directly, potassium hydroxide causes cells affected by the molluscum virus to dissolve, producing an inflammatory reaction in the affected skin, after which healing occurs.1

Clinical studies

Potassium hydroxide 5% solution showed efficacy in a clinical study involving 21 children aged two to 13 years with multiple molluscum contagiosum lesions that had been present for four to eight months. The solution was applied twice daily to each lesion until an inflammatory reaction was visible in all lesions.2

Time to development of inflammation or superficial ulceration was three to six days, with complete resolution of symptoms observed after 14 to 35 days. No recurrences were seen during two to eight months of follow-up.2

In another open-label study, potassium hydroxide 5% solution was compared with tretinoin 0.05% cream in 50 children aged six months to 14 years with molluscum contagiosum. Both treatments were applied once daily at bedtime.3

After four weeks, patients responded well to both treatments, with the mean lesion count decreasing from 9.48 (+/-3.00 SD) to 1.67 (+/-0.58 SD) in the potassium hydroxide group (n = 23) and from 8.35 (+/-2.82 SD) to 2.00 (+/-1.00 SD) in the tretinoin group (n = 23).3

Crusting and oedema were more common with potassium hydroxide, while scaling and dryness were more common with tretinoin.3

New actinic keratosis option

Zyclara is a cream containing 3.75% imiquimod, for the topical treatment of non-hyperkeratotic and non-hypertrophic actinic keratosis of the face and scalp. It is indicated when other topical treatment options are contraindicated or less appropriate.

Imiquimod is an immune response modifier that has been shown to increase systemic levels of interferon alfa and other cytokines following topical application.4 It is already available as a 5% cream (Aldara) for use in the treatment of superficial basal cell carcinoma and external genital and perianal warts, as well as actinic keratosis.

Clinical studies

The safety and efficacy of imiquimod were evaluated in two double-blind, placebo-controlled studies involving 319 patients with five to 20 typical visible or palpable AK lesions of more than 25cm2 on the face or scalp.5

Up to two sachets of imiquimod 3.75% cream or a matching vehicle cream were applied to the entire face or balding scalp once daily for two two-week treatment cycles separated by a two-week treatment-free period.5

Overall, 35.6% of patients treated with imiquimod 3.75% cream had complete clearance eight weeks post-treatment compared with 6.3% of those treated with placebo.5 The most commonly reported side-effects are application site reactions, including erythema, scabbing, exfoliation and dryness.4

References

1. MolluDab Package Insert, October 2012.

2. Jansen T et al. Akt Dermatol 2007; 33: 210-15.

3. Rajouria EA et al. Kathmandu Univ Med J 2011; 36: 291-4.

4. Zyclara Summary of Product Characteristics, August 2012.

5. Swanson N et al. J Am Acad Dermatol 2010; 62: 582-90.


Read these next

New product update

New product update

A round-up of the latest developments in pharmaceuticals,...

New product update

New product update

A round-up of the latest developments in pharmaceuticals,...


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.